Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis

S Matthijs Boekholdt, Benoit J Arsenault, G Kees Hovingh, Samia Mora, Terje R Pedersen, John C LaRosa, K M A Welch, Pierre Amarenco, David A DeMicco, Andrew Maxwell Tonkin, David Sullivan, Adrienne Kirby, Helen Colhoun, Graham H Hitman, D John Betteridge, Paul N Durrington, Michael B Clearfield, John R Downs, Antonio M Gotto, Paul M RidkerJohn J P Kastelein

Research output: Contribution to journalArticleResearchpeer-review

120 Citations (Scopus)


It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk. METHODS AND RESULTS-: We performed a meta-analysis of 8 statin trials in which lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up. Individual patient data were obtained for 38 153 trial participants allocated to statin therapy, of whom 5387 suffered a major cardiovascular event. HDL-C levels were associated with a reduced risk of major cardiovascular events (adjusted hazard ratio [HR], 0.83; 95 confidence interval [CI], 0.81-0.86 per 1 standard deviation increment), as were apoA-I levels (HR, 0.79; 95 CI, 0.72-0.82). This association was also observed among patients achieving on-statin low-density lipoprotein cholesterol levels
Original languageEnglish
Pages (from-to)1504 - 1512
Number of pages9
Issue number14
Publication statusPublished - 2013

Cite this